CD200 Expression in B-cell chronic lymphoproliferative disorders

Journal of Investigative Medicine

Volumn 60, Issue 1, 2012, Pages 56-61

  El Desoukey, Nermeen Ahmed ^a   Afify, Reham Abd Aleem ^a   Amin, Dalia Gamil ^a   Mohammed, Rasha Faragaly ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Clinical Pathology   (Egypt)

Author keywords

BCLPDs; CD200; Flow cytometry

Indexed keywords

CD103 ANTIGEN; CD19 ANTIGEN; CD200 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ARTICLE; B CELL CHRONIC LYMPHOPROLIFERATIVE DISEASE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; MANTLE CELL LYMPHOMA; SPLENIC MARGINAL ZONE LYMPHOMA;

EID: 84856690634     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31823908f9     Document Type: Article

References (36)

1. Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33: 12-17.
2. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10): 1640-1645. (Pubitemid 24323778)
3. Dogan A. Modern histological classification of low grade B-cell lymphomas. Best Pract Res Clin Haematol. 2005;18(1): 11-26. (Pubitemid 40197863)
4. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol. 2001;38(2): 111-123. (Pubitemid 32319311)
5. Braylan RC. Impact of flow cytometry on the diagnosis and characterization of lymphomas, chronic lymphoproliferative disorders and plasma cell neoplasia. Cytometry. 2004;58A(part A): 57-61. (Pubitemid 38337831)
6. Kurtin PJ, Hobday KS, Ziesmer S, et al. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol. 1999;112(3): 319-329. (Pubitemid 30214770)
7. Garcia DP, Rooney MT, Ahmad E, et al. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol. 2001;115(2): 258-265. (Pubitemid 32150685)
8. Babusikova O, Tomova A, Kusenda J, et al. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment. Neoplasma. 2001;48(5): 350-357. (Pubitemid 33144711)
9. Morice W, Kurtin P, Hodnefield J, et al. Predictive value of blood and bone marrow flow cytometry in b-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clinic Proc. 2008;83(7): 776-785.
10. Gong JZ, Lagoo AS, Peters D. Value of CD23 determination by flowcytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116: 893-897. (Pubitemid 33108161)
11. DiRaimondo F, Albitar M, Huh Y, et al. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002;94: 1721-1730. (Pubitemid 34241110)
12. Jain P, Giustolisi GM, Atkinson S, et al. Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry. J Clin Pathol. 2002;55: 940-945. (Pubitemid 35454498)
13. Chen CC, Raikow RB, Sonmez-Alpan E, et al. Classification of small B cell lymphoid neoplasms using a paraffin section immunohistochemical panel. Appl Immunohistochem Mol Morphol. 2000;8: 1-11. (Pubitemid 30152347)
14. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106: 4315-4321. (Pubitemid 41775942)
15. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82: 567-575. (Pubitemid 28112997)
16. Cuneo A, Balboni M, Piva N, et al. Atypical chronic lymphocytic leukemia with t(11;14)(q13;q32): karyotype evolution and prolymphocytic transformation. Br J Haematol. 1995;90: 409-416.
17. Swerdlow SH, Zukerberg LR, Yang WI, et al. The morphologic spectrum of non Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements. Am J Surg Pathol. 1996;20: 627-640. (Pubitemid 26129450)
18. Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23: 285-290. (Pubitemid 34628770)
19. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 2008;29: 464-468.
20. Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukemia neoplastic cells. BJH. 2009;145: 665-678.
21. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108: 4194-4197. (Pubitemid 44913292)
22. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol. 2010;134(5): 726-733.
23. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2011;35(1): 76-83.
24. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukemia. Leukemia. 2007;21: 566-568.
25. Moreaux J, Veyrune JL, Reme T, et al. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366: 117-122. (Pubitemid 350297222)
26. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997;108: 378-382. (Pubitemid 27411287)
27. Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias Diagnostic utility and critical analysis of data. Arch Pathol Lab Med. 2003;127: 42-48. (Pubitemid 36236578)
28. Tiacci E, Liso A, Piris M, et al. Evolving concepts in the pathogenesis of hairy cell leukaemia. Nature Reviews Cancer. 2006;6: 437-448.
29. McWhirter J, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. PNAS. 2006;103: 1041-1046. (Pubitemid 43212218)
30. Petermann KB, Rozenberg GI, Zedek D, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest. 2007;117: 3922-3929. (Pubitemid 350224101)
31. Smal C, Lisart S, Maerevoet M, et al. s2-Chloro-2-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB. Biochem Pharmacol. 2007;73: 351-358.
32. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7: 750-762. (Pubitemid 47463673)
33. Wong K, Shaha S, Spaner D, et al. Potential role for serum soluble cd200 in human chronic lymphocytic leukemia. J Immunology. 2009;182: 88.15.
34. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology. American Society of Hematology, Education program book, 2004;163-183.
35. Robak T. Rituximab combined with cladribine or with cladribine and cyclo-phosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Leuk Lymphoma. 2004;45: 205-219.
36. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007;178: 5595-5605. (Pubitemid 46674355)